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Abstract 
Introduction: The treatment of hepatitis C virus (HCV) infection has dramatically improved in 
recent years with the widespread use of interferon-free combination regimens. Despite the high 
sustained virological response (SVR) rates (over 90%) obtained with direct-acting antivirals 
(DAAs), drug resistance has emerged as a potential challenge. The high replication rate of HCV and 
the low fidelity of its RNA polymerase result in a high degree of genetic variability in the HCV 
population, which ultimately explains the rapid selection of drug resistance associated variants 
(RAVs). 
Areas covered: Results from clinical trials and real-world experience have both provided important 
information on the rate and clinical significance of RAVs. They can be present in treatment-naive 
patients as natural polymorphisms although more frequently they are selected upon treatment 
failure. In patients engaged in high-risk behaviors, RAVs can be transmitted. 
Expert opinion: Although DAA failures generally occur in less than 10% of treated chronic 
hepatitis C patients, selection of drug resistance is the rule in most cases. HCV re-treatment options 
are available, but first-line therapeutic strategies should be optimized to efficiently prevent DAA 
failure due to baseline HCV resistance. Considerable progress is being made and next-generation 
DAAs are coming with pangenotypic activity and higher resistance barrier. 
 
Keywords: drug resistance, HCV, resistance testing, simeprevir, sofosbuvir, NS5A inhibitors 
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Article highlights box 
 
 
 The rapid development of DAAs has replaced interferon-based regimens as HCV therapy. 
However, the effectiveness of DAAs may be compromised by drug resistance. 
 
 NS3/4A inhibitors and NS5A inhibitors display low barrier to resistance and broad cross-
resistance to compounds within the same drug family. However, combination DAA therapy 
generally allows to overcome antiviral resistance. 
 
 Sofosbuvir exhibits a high barrier to resistance, being mutation S282T rarely been recognized in 
vivo. 
 
 RAVs causing resistance to NS5A inhibitors tend to compromise SVR in patients with 
advanced cirrhosis, infection with genotype 1a and 3 and/or prior interferon failure.  
 
 The elevated costs of all-oral DAA therapies may push tailoring therapy; DAA resistance 
testing may be useful to help to identify the most convenient (cost-effective) treatment and 
retreatment option for each patient.  
 
 Viral gene sequencing may recognize RAVs, with rates depending on HCV geno/subtype and 
sensitivity of methods used. 
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1. Introduction 
 
Hepatitis C virus (HCV) is a leading cause of chronic liver disease which can progress to cirrhosis 
and hepatocellular carcinoma (HCC) and it is the most common indication for liver transplantation 
in Europe and the United States [1]. According to WHO reports, approximately 120 million people 
worldwide are infected with HCV, with an estimated global prevalence of 2-3% [2]. 
 
Until 2011, the combination of pegylated-interferon (pegIFN) and ribavirin (RBV) was the standard 
treatment for HCV infection, leading to sustained virologic response (SVR) rates below 40% in 
HCV genotypes (GT) 1 and 4. Besides its limited effectiveness, interferon-based therapy was 
associated with a long treatment duration and with frequent and severe adverse effects, especially in 
cirrhotic patients. 
 
The advent of direct acting antivirals (DAAs) has revolutionized therapeutic options for patients 
with HCV. New oral interferon-free therapies provides cure rates above 90% in most patients, 
regardless geno/subtype, prior IFN-experience, and fibrosis stage [3,4]. However, the effectiveness 
of new DAAs may be compromised by the rapid development of resistance-associated variants 
(RAVs) [5].  
 
Currently available DAAs are classified into four categories on the basis of their molecular target in 
the viral lifecycle and mechanism of action: NS3/4A protease inhibitors, NS5A inhibitors, 
nucleotide analogue inhibitors of NS5B RdRp and non-nucleoside inhibitors of RdRp. The high 
specificity of DAAs against their viral targets makes them sensitive to small changes in the viral 
sequence, resulting in emergence of antiviral resistance which plays a key role in IFN-free 
treatment failure. Given the large HCV genetic variability, the outcome of DAA-based therapies 
may be altered by the selection of mutations at different positions in the NS3 protease, NS5B 
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polymerase and NS5A protein which affect viral susceptibility to the administered compounds. 
Each drug or class of DAAs is characterized by a specific resistance profile that influences the 
genetic barrier to resistance and differ between viral geno/subtypes [6] as shown in Table 1. 
Currently, different interferon-free combination therapies with DAAs are approved (Table 2) and 
should provide additive or synergistic antiviral potency and prevent the emergence of DAAs 
resistance [7].  
 
A sequence diversity analysis at drug resistance-associated aminoacid positions is important to 
evaluate the risk of naturally occurring resistance-related variants present at baseline or the risk for 
development of drug resistance variants under drug selective pressure [5]. The identification of 
treatment-emergent resistant variants as well as the impact of preexisting baseline mutations on 
treatment outcome in patients failing treatment with DAA therapy is essential to predict the rate of 
cure with distinct DAA combinations and to assess treatment and retreatment options. 
 
2. HCV variability and emergence of Resistance Associated Variants (RAVs) 
 
The combination of a high HCV replication rate, the low fidelity of HCV polymerase and the 
selective pressures exerted by the host immune system has driven the evolution of HCV towards the 
development of a global diversity. Phylogenetic and sequence analysis of entire viral genomes splits 
HCV into seven major distinct genotypes and more than 60 subtypes [8].  
 
HCV has a high rate of turnover with 10
10
 to 10
12
 virions produced per day in an infected patient. 
The RdRp of HCV has a poor fidelity because it lacks an exonucleolytic proofreading activity. 
Therefore, HCV replication is error-prone with an error rate of 10
-3
 to 10
-5
 mutations per nucleotide 
per genomic replication cycle. Consequently, the virus population in a chronic HCV infection exists 
as a group of genetically distinct but closely related variants, termed “quasispecies” [9]. While the 
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majority of those variants are cleared by the host immune system or are unable to replicate as a 
result of mutations that confer loss of function to essential HCV encoded proteins, some variants 
remain replication competent. Thus, within an HCV-infected individual, this heterogeneous pool of 
genetic variants consists of a dominant (or “wild-type”) HCV strains that replicates to high 
efficiency, within a background of less fit HCV variants present at lower frequencies [10]. 
Moreover, some of these minor viral variants can carry aminoacid substitutions which determine 
conformation changes of a drug-target binding site, and are therefore less susceptible to the drug’s 
inhibitory activity, subsequently leading to a virological breakthrough during treatment or a relapse 
after treatment cessation [11]. Although these drug resistant variants represent only minor 
percentages of the total virus population (frequencies <1%), they can be selected and become the 
predominant viral species during drug exposure, as shown in Figure 1.  
 
It is therefore not surprising that RAVs naturally occur in HCV-infected treatment-naive patients 
[12]. The frequency of baseline RAVs is extremely variable and depends on many factors, such as 
the replicative fitness of the natural variant, the characteristic of the drug administered, the drug-
binding region in the HCV genome and the viral geno/subtype. 
 
The likelihood that a drug will select for and allow outgrowth of viral variants carrying resistance-
associated mutations within the quasispecies depends on several factors including (i) the drug’s 
genetic barrier to resistance, (ii) the viral fitness of the resistant variant, and (iii) drug selective 
pressure [13]. 
 (i) The genetic barrier to resistance refers to the number and type of nucleotide changes needed to 
result in aminoacid substitutions required to acquire resistance to the antiviral drug and is different 
between genotypes and also varies on the HCV subtype level. When a single aminoacid substitution 
is sufficient to confer a high-level resistance, the drug is considered to have a low genetic barrier, 
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whereas a drug with a high genetic barrier requires multiple mutations within the HCV genome to 
generate a resistant variant. 
 (ii) The replication fitness of a resistant variant is defined as its ability to survive and replicate in a 
highly mutagenic environment. A selected resistant variant must be able to replicate efficiently in 
order to ﬁll in the replication space left vacant by the susceptible “wild-type” virus during drug 
exposure. Therefore, a highly resistant but poorly ﬁt variant may not emerge to become the 
dominant viral species under drug selection pressure and will be less clinically significant than a 
variant with a preserved replication fitness that can replicate efficiently in the presence of the drug.  
(iii) The drug selective pressure is influenced by the drug potency, the level of drug exposure, 
defined as the drug concentration achieved in vivo relative to the IC50-IC90/EC50-EC90 values of 
resistant variants, and the patient adherence to therapy. 
 
3. Major HCV resistance patterns and mutations 
 
3.1 Resistance to NS3/4A Protease Inhibitors 
The NS3/4A protease inhibitors (PIs) bind to the catalytic site of the enzyme and block post-
translational processing of the viral polyprotein at cleavage sites, preventing the release of 
functional proteins, necessary for the production of infectious viral particles.  
First-generation HCV PIs telaprevir and boceprevir are no longer recommended, given their limited 
efficacy (restricted to GT1), troublesome toxicities and low genetic barrier to resistance and 
considerable cross-resistance. The second wave of first generation PIs includes simeprevir, 
asunaprevir, paritaprevir and vaniprevir. These drugs exhibit an improved safety profile, a higher 
genetic barrier to resistance and a better antiviral activity against multiple genotypes, except GT3.  
 
A summary of NS3/4A protease inhibitors resistance associated mutations is given in Table 3. 
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3.1.1 Simeprevir  
Simeprevir (SMV) was approved to be used with pegIFN/RBV or as part of all-oral regimens in 
patients with HCV GT1 or GT4 who are treatment-naive and prior treatment-failures. 
Resistance to SMV was reported in vitro for several aminoacid changes at key position in NS3: 
80,122,155 and 168 [14]. Results from QUEST-1 and QUEST-2 phase III trials assessing the 
efficacy and safety of the combination of SMV plus pegIFN/RBV in treatment-naive GT1 patients 
confirmed the replicon studies [15,16]. Most patients with treatment failure had emerging mutations 
in the HCV NS3 protease domain, which were mainly D168V in patients with GT1b or R155K 
alone or in combination with aminoacid substitutions at positions 80 or 168 in those with GT1a. 
Pre-treatment natural resistance to SMV is rare among HCV GT1-infected patients [17]; however, 
Q80K variant is associated with a much higher natural prevalence in HCV subtype 1a isolates, 
leading to reduced susceptibility to SMV when combined with pegIFN/RBV [15,16], but not in 
association with the nucleos(t)ide NS5B polymerase inhibitor sofosbuvir (SOF) as pointed out in 
the COSMOS randomised study [18]. 
The OPTIMIST-1 and 2 studies showed that the effect of Q80K on clinical outcome to SMV plus 
SOF seems to be substantially attenuated or possibly eliminated. High SVR12 rates were achieved, 
including in subjects with baseline Q80K, showing the strength of combinatorial treatment [19,20].  
No data is available for GT4, the other indication of this combination. 
 
3.1.2 Asunaprevir   
Asunaprevir (ASV) has been approved in Japan in combination with the NS5A inhibitor daclatasvir 
(DCV) in patients chronically infected with HCV GT1b. 
In HCV replicon systems and in short-term ASV monotherapy studies [21], the most commonly 
NS3 substitutions identified were R155K and D168E, which conferred low- to moderate-level ASV 
resistance in GT1a, and D168V associated with high-level ASV resistance in GT1b. 
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The impact of pre-existing drug-resistant substitutions on clinical outcome of the combination 
treatment with DCV and ASV was studied in GT1b infected patients [22,23]. While pre-existing 
DCV-resistant variants at positions 31 or 93 might compromise the response to this regimen, no 
ASV-resistant variants were detected at baseline. However, treatment failure was associated with 
the emergence of both NS5A-L31/Y93 and NS3-D168 variants. While ASV-RAVs that emerged 
during therapy returned to wild-type, DCV-resistant variants tended to persist in the absence of the 
drug, suggesting a higher relative fitness of NS5A variants [24]. 
 
3.1.3 Paritaprevir  
Paritaprevir is coadministered with the pharmacokinetic enhancer ritonavir (paritaprevir/r) and 
approved in combination with the non-nucleoside NS5B inhibitor dasabuvir and the NS5A inhibitor 
ombitasvir ± RBV for treatment of GT1-infected patients. This interferon-free regimen is referred to 
as 3-drug combination (3D). 
Aminoacid variants conferring resistance to paritaprevir were detected in NS3 at positions 155 and 
168 in GT1a and at positions 156 and 168 in GT1b, in vitro or following monotherapy, with the 
D168V variant conferring the highest level of resistance to paritaprevir in both subtypes [25]. 
These findings are consistent with resistance analyses conducted in the AVIATOR phase II trial in 
which the most prevalent NS3 treatment-emergent variant among patients with virologic failure 
were D168V and R155K [26].  
The phase 3 SAPPHIRE-I and SAPPHIRE-II trials evaluating the safety and efficacy of the 
combination of paritaprevir/r-ombitasvir and dasabuvir with RBV in HCV GT1 infected patients 
naive or previously treated with pegIFN/RBV, respectively [27,28], showed that the patients who 
experienced virologic failure during treatment or relapse had at least one aminoacid variant that was 
known to confer resistance to one of the three DAA agents included in the regimen. The most 
frequently detected variants in patients with GT1a infection who did not achieve SVR were D168V 
in the protein NS3, M28T/V and Q30R in the protein NS5A, and S556G/R and M414T in the 
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protein NS5B. The GT1b-infected with virologic failure had Y56H and D168A/V in NS3, L31M 
and Y93H in NS5A, and C316N and S556G in NS5B.  
No data are available for the 2D regimens of ombitasvir and paritaprevir/r (without dasabuvir) in 
patients infected with HCV GT4. 
 
3.1.4 Vaniprevir  
Vaniprevir is an investigational PI currently approved only in Japan, which exhibits potent antiviral 
activity in GT1-infected patients when added to pegIFN/RBV.  
In vitro resistance selection experiments and sequence data from Phase I and II clinical studies have 
identified several NS3 variants at positions R155, A156 and D168 associated with decreased 
susceptibility to vaniprevir [29].  
RAVs from patients failing to achieve SVR on vaniprevir-containing regimens from a trial of triple-
combination therapy were R155K and D168T/V/Y in GT1a patients and D168H/T/V in GT1b-
infected patients. Moreover, R155K variants were observed at baseline in 2 naive patients, who 
subsequently experienced virologic failure [30]. It is difficult to draw general conclusions from this 
observation, however, due to the limited data set. 
 
3. 2. Resistance to NS5B Polymerase Inhibitors 
The NS5B polymerase inhibitors which interfere with viral replication by binding to the NS5B 
RdRp can be divided into two distinct categories [31]. 
Nucleos(t)ide analogue inhibitors (NIs) mimic the natural substrates of the polymerase and are 
incorporated into the nascent RNA chain causing direct chain termination. This class of DAA 
shows a high potency, a pan-genotypic activity and a high genetic barrier to resistance because the 
active site of the HCV NS5B polymerase is strongly conserved among all HCV genotypes. 
Non-nucleoside inhibitors (NNIs) usually bind to several discrete sites on the HCV polymerase, 
which results in conformational protein changes before the elongation complex is formed. A 
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limitation of this mechanism of action is that these allosteric binding sites are less conserved among 
genotypes compared to the active site. As a consequence, lower cross-genotypic activity and higher 
probability of resistance development is observed.   
 
A summary of NS5B polymerase inhibitors resistance associated mutations is given in Table 4. 
 
3.2.1 Sofosbuvir  
Sofosbuvir (SOF) is the first nucleos(t)ide NS5B polymerase inhibitor approved for the treatment of 
HCV infection as part of IFN-based and IFN-free regimens.  
Using HCV replicon systems, the S282T mutation was most commonly selected. The S282T known 
as signature NS5B mutation associated with resistance to SOF from in vitro studies, has been rarely 
detected at baseline in Phase II or III SOF-containing clinical trials.; this could be explained by the 
low replicative ﬁtness of this variant [32]. 
However, in the ELECTRON trial, the S282T substitution was detected in a patient infected with 
HCV GT2 who suffered a virologic relapse after 12 weeks of SOF monotherapy [33]. 
This polymorphism was also found in two GT1-infected patients who relapsed after treatment with 
SOF/RBV for 24 weeks [34] and with SOF plus the NS5A inhibitor ledipasvir for 8 weeks [35], 
respectively.  
In a pooled analysis of SOF phase III clinical trials for which drug resistance analyses were 
performed, low-frequency treatment-emergent NS5B substitutions including L159F and V321A 
were associated with virological failure in some SOF-treated subjects [36]. 
In a pooled analysis of SOF phase III clinical trials (FISSION, POSITRON, FUSION and 
NEUTRINO) for which drug resistance analyses were performed, low-frequency treatment-
emergent NS5B substitutions including L159F and V321A emerged in several patients infected 
with HCV GT3 who experienced post-treatment relapse. 
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3.2.2 Dasabuvir  
Dasabuvir (DSB) currently is the only non-nucleoside NS5B inhibitor binding to the palm I site 
approved as a component of the 3D combination. 
A number of RAVs have been selected in HCV replicon or monotherapy studies at several 
aminoacid positions in the NS5B protein: S556G and C316Y in GT1a, while C316Y and M414T in 
GT1b. The C316Y variant in both subtypes conferred >900 fold resistance to DSB [37]. 
 
3.3 Resistance to NS5A Inhibitors 
The NS5A inhibitors target the Domain I of NS5A protein and block phosphorylation of NS5A, 
which is important for viral replication assembly and release of HCV particles. 
HCV NS5A inhibitors are likely to be a component of any multi-drug combination regimens with 
pan-genotypic activity potent enough to prevent the emergence of resistance mutations. Currently, 
available NS5A inhibitors are daclatasvir, ledipasvir and ombitasvir. Although NS5A inhibitors are 
quite potent and have a broad genotypic coverage (which is explained by a more conserved 
interaction site within the NS5A protein), they are also characterized by their relatively low viral 
barrier to resistance and long-time persistence of RAVs, as viral fitness seems not to be impaired 
[24]. All resistance mutations to this class of inhibitors were mapped to the N-terminal region of 
NS5A (domain I).  
 
A summary of NS5A inhibitors resistance associated mutations is given in Table 5. 
 
3.3.1 Daclatasvir  
Daclatasvir (DCV) shows a very potent antiviral effect on several HCV genotypes.  
NS5A mutations emerged in vivo and associated with failure of DCV mono- or combination-
therapy are similar to those selected in the HCV replicon system or with the infectious clone [38]. 
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The primary resistance conferring mutations observed in vivo for GT1a infected patients who did 
not achieve SVR were M28T, Q30E/H/R, L31M/V, P32L, H58D and Y93H/N and for GT1b the 
major resistance substitutions were L31M/V, P32L and Y93H/N. 
NS5A residues 30, 31 and 93 were the major sites associated with resistance to DCV in most of the 
genotypes [39], suggesting that the location of the DCV binding site is conserved among diverse 
HCV strains.  
Due to a relatively low genetic barrier, DCV was developed as part of an interferon-free dual 
therapy in combination with asunaprevir. Subsequently, the impact of baseline polymorphisms 
associated with loss of susceptibility to NS5A inhibitors was evaluated in an open-label phase III 
clinical trial of DCV plus asunaprevir in GT1-infected patients. This study highlighted that the 
presence of mutations at aminoacids L31 and Y93 may reduce the barrier to resistance and 
influence virologic outcome for those patients who carry these polymorphisms at baseline [40].  
More recently, the results of safety and efficacy for the combination DCV plus sofosbuvir for 
previously treated or untreated chronic HCV GT1-infected patients have been published. In this 
study, although the prevalence of baseline polymorphisms associated with DVC resistance was 
around 8%, all but one patient achieved SVR [41]. 
 
3.3.2 Ledipasvir  
Ledipasvir (LDV) was approved in combination with sofosbuvir against HCV genotypes 1a and 1b. 
The NS5A aminoacid substitutions Q30E/R, L31M and Y93C/H/N in GT1a and Y93H in GT1b, 
both in cell culture and in clinical trials, have been associated with high levels of reduced 
susceptibility to LDV [42,43]. 
In phase II and III clinical trials, the combination of LDV/SOF ± RBV resulted in high rates of SVR 
among untreated and previously treated patients with HCV GT1 infection, including those with 
compensated cirrhosis [44-46]. Although virological failure was rare using this DAA regimen, 
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NS5A-resistant variants have been found in half of the patients who relapsed both at baseline and at 
the time of relapse, without NS5B RAVs. 
  
3.3.3 Ombitasvir  
Ombitasvir is an HCV NS5A inhibitor with pan-genotypic efficacy, co-formulated as a single tablet 
with the PI paritaprevir/ritonavir and administered along with the NNI dasabuvir in the 3D 
combination regimen.  
The in vitro profile of ombitasvir and the results in the 3-day monotherapy study identified variants 
conferring resistance at aminoacid position 28, 30, 31, 58 and 93 in the NS5A gene across 
genotypes 1 to 6; however, the resistance conferred by variants at these aminoacid positions to 
ombitasvir varied by genotype [47].  
 
3.4. Next generation DAA therapies 
As the availability of broad pan-genotypic DAAs remains scarce and the emergence of resistance 
remains challenging, there is still a search for more potent DAA combination therapies with 
increasing SVR rates and shorter treatment duration. The second-generation DAAs exhibit 
improved barrier to resistance as they aim to overcome restrictions in terms of resistance profile of 
the previous drug classes as well as concerning the coverage of distinct HCV geno- and subtypes. In 
the coming years, 2016/17, hopefully at least three other DAA-based combinations could be 
approved: grazoprevir in co-formulation with elbasvir, sofosbuvir with velpatasvir +/- voxilaprevir, 
ABT-493 plus ABT-530 combination therapy.  
 
3.4.1. Grazoprevir/Elbasvir 
Grazoprevir (GZR), a HCV protease inhibitor has been approved in the United States in 2016 in 
combination with the NS5A inhibitor elbasvir (EBR) either ± RBV for the treatment of chronic 
Hepatitis C Virus Genotype 1 or 4 infection. Due to their improved structure, GZR and EBR 
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showed, in vitro, increased potency against some common clinical NS3 and NS5A RAVs selected 
by previous first generation compounds. 
Virologic findings in patients treated with GZR/EBR from phase II and III clinical studies were 
consistent with the preclinical observations. This therapy combines two DAA agents with distinct 
action mechanisms and non-overlapping resistance profiles to target HCV at multiple steps in the 
viral lifecycle, resulting in SVR12 rate up to 95%, even in difficult to treat patients such as 
cirrhotic, HIV co-infected, or those who previously failed antiviral therapy [48]. 
The C-SALVAGE study demonstrated that GZR/EBR combination plus RBV for 12 weeks 
provides a promising retreatment option for HCV-infected patients with genotype 1 with a history 
of failure on a triple regimen containing earlier-generation protease inhibitor [49]. 
SVR12 was attained in the 91% of the patients with prior virologic failure harboring virus with 
documented NS3 RAVs conferring decreased susceptibility to boceprevir, telaprevir, and/or 
simeprevir at baseline. This new regimen exerts a potent effect on HCV RNA replication and 
presents a high genetic barrier to resistance and not cross-resistance to the failed protease inhibitor.  
The presence of NS3 RAVs at baseline did not significantly affect the efficacy of GZR/EBR ± 
RBV, although NS5A baseline RAVs had some effect on SVR12 . Results from the C-WORTHY 
trial suggests that pre-existing NS5A RAVs pose a bigger clinical problem than NS3/4A RAVs 
(SVR12 82% vs 92%) [50]. Although EBR shows a higher barrier of resistance, NS5A 
polymorphisms at the same positions as for first generation HCV NS5A inhibitors were observed in 
patients with treatment failure (M28, Q30, L31, Y93), especially in genotype 1a patients. 
 
3.4.2. Sofosbuvir/velpatasvir +/- voxilaprevir 
Promising pan-genotypic regimens in development are the co-formulation of sofosbuvir with the 
second generation NS5A inhibitor, velpatasvir (VEL) and SOF/VEL plus voxilaprevir (VOX), an 
experimental macrocyclic HCV NS3/4A protease inhibitor. 
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In ASTRAL phase III clinical trials, a fixed-dose combination of SOF/VEL for 12 weeks was 
highly effective in both treatment -naïve and -experienced patients, infected with genotypes 1 to 6, 
including those with compensated and decompensated cirrhosis and those who did not achieve SVR 
after prior treatment with other DAA regimens. At baseline, the presence of NS5A resistance-
associated variants had no impact on SVR (99% ) in patients infected with genotypes 1a, 1b, 2, 4, 5 
and 6 in whom only two virologic failures occurred, both in patients with HCV genotype 1 
infection. Those two patients who had a relapse, had NS5A-resistant variants at baseline (Q30R and 
L31M) and at the time of relapse (Y93H) [51]. 
Otherwise, among patients with HCV genotype 3, the rate of SVR was 88% in patients who had 
NS5A resistance-associated variants at baseline and 97% among those who did not, with the lowest 
rate (84%) observed among patients with the Y93H variant at baseline [52]. 
Data from a phase II clinical trial demonstrated that the combination SOF/VEL plus VOX for 8 
weeks was effective, achieving SVR rates over 95% across different patient populations including 
previously difficult-to-treat patients with cirrhosis, genotype 3 HCV infection and previous 
nonresponse to treatment. In addition, VOX and VEL retain potent activity in the presence of most 
commonly detected NS3 and NS5A RAVs, respectively. No specific baseline NS3, NS5A, or NS5B 
RAV alone or in combination predicted virologic failure, even for those patients with prior 
treatment experience [53]. Baseline RAVs, including Y93H, the only NS5A substitution which 
confers high-level resistance to velpatasvir, did not appear to affect response to short durations of 
this treatment, confirming a very high barrier to resistance of this regimen and further suggesting its 
potential as a salvage regimen for DAA-experienced patient with longer treatment duration.  
 
3.4.3. ABT-493/ABT-530 
One of the exciting new combinations with several phase II clinical trials results being presented is 
the new second generation HCV protease inhibitor ABT-493 and the NS5A inhibitor ABT-530. In 
vitro, both compounds demonstrated potent pan-genotypic antiviral activity, with a high barrier to 
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resistance and maintained potent antiviral activity against key RAVs that often negatively affect the 
potency of other DAAs . 
Moreover, the presence of baseline NS3 and NS5A RAVs did not appear to affect viral load 
declines during ABT-493 and ABT-530 monotherapy, respectively in treatment-naive adults with 
HCV genotype 1 infection, with or without compensated cirrhosis [54]. Taken together, these 
results suggest that the combination of these next-generation DAAs holds promise for more 
difficult-to-treat patients who harbor NS5A RAVs that are known to confer resistance to currently 
approved NS5A inhibitors. The combination of ABT-493 and ABT-530 has been advanced into 
phase II clinical studies in both treatment-naive and previously treated HCV patients with patients 
with genotype 1 to 6 infections, including patients with compensated cirrhosis, achieving 
encouraging SVR rates between 97-100%. 
 
4. RAVs before and after treatment failure 
 
4.1. Clinical significance of baseline RAVs 
The error-prone nature of HCV polymerase determines that pre-treatment RAVs are likely to occur. 
Indeed, standard population sequencing and NGS technologies have described the natural existence 
of RAVs for all DAAs classes [55-57].  
 
RAVs may be present in the inherent sequence of some genotypes and subtypes which could 
explain the reduced activity of certain DAAs to different HCV genotypes. For example, S556G 
which confers resistance to dasabuvir is present in 97-100% of HCV genotypes 2, 3, 4 and 5 
isolates. The high frequency of this natural variant, together with RAVs at other positions within the 
NS5B polymerase (M289I/L, C316N), could explain the lack of antiviral activity of this DAA in 
non-HCV genotype 1 infected patients [57]. 
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It is currently unclear which frequency of RAVs is clinically relevant for the prediction of virologic 
treatment failure as the impact of pre-treatment RAVs on therapy efficacy is also variable. Several 
clinical studies have revealed that in most cases, the pre-existence of a RAV is not always related to 
treatment failure, thus suggesting that many others factors are also implicated. First, the level of 
resistance of a certain RAV is not necessarily related to treatment failure in a DAA-based antiviral 
therapy. For example, Q80K -a low level RAV to NS3 PIs- significantly influences virologic 
treatment outcome in a triple therapy with SMV/pegIFN/RBV; whereas for the combination therapy 
of SMV/SOF the baseline presence of Q80K seems to be less relevant [18,58,59]. Secondly, in 
some cases, viral and host negative predictors of virologic treatment response together with baseline 
RAVs seem to be of clinical relevance. It has been reported that for the combination therapy of 
SOF/LED, response to antiviral therapy depends not only on the pre-existence of high level 
resistance NS5A variants (for example, Y93H with a baseline frequency of 3.8-14.1% in HCV 
GT1b patients), but also on other predictive factors, such as treatment duration and the stage of liver 
fibrosis [60]. Finally, the antiviral activity and the genetic barrier to resistance of the chosen DAA 
or combination of different drug classes influence therapy response. In fact, it has been reported that 
the pre-existence of RAVs seems to have a greater impact on treatment schemes that include DAAs 
with low barrier to resistance; whereas for regimens with DAAs with high antiviral activities and 
high genetic barrier to resistance the presence of baseline resistance leads only to a small reduction 
of SVR rates [5].  
 
4.2. Persistence of RAVs 
In HIV and HBV infection, resistant variants are archived for prolonged periods after virologic 
failure and reselected during retreatment with the same type of drug [61,62] based on their 
replication with stable DNA intermediates. In contrast, in the case of HCV, studies are 
contradictory. While in some reports no evidence for long-term persistence and re-selection of 
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isolates with RAVs during retreatment with the same drug was observed, in others indirect evidence 
pointed to the possibility of persistence and re-selection [63-65] 
 
After stopping DAA treatment, the frequency of many RAVs with impaired replicative fitness 
within the HCV quasispecies rapidly decline to levels undetectable by population and clonal 
sequencing [66,67]. For example, immediately after treatment failure with telaprevir and 
boceprevir, 82% of patients exhibited RAVs, but persistent variants were detected one year later 
only in 18% of HCV GT1a infected patients [68]. In the case of patients with repeated protease 
inhibitor-based therapy, clonal and deep sequencing analysis revealed a continuous evolution of the 
NS3 genomic region with no clear evidence of persistence and reselection of RAVs but strong signs 
of independent de novo generation of resistance [65]. 
 
In contrast, RAVs to NS5A inhibitors are associated with high replicative fitness and frequently 
additional compensatory mutations. Indeed, in clinical studies it has been reported persistence of 
NS5A RAVs over 1-2 years after treatment failure in over 85% of patients [69-70]. After 24 weeks 
of retreatment with sofosbuvir plus ledipasvir, in patients with detectable NS5A RAVs at baseline 
the overall SVR rate was 60% which highlights the importance of persistent NS5A RAVs for the 
selection of effective retreatment options [35].  
 
Regarding the long-time persistence of NS5B RAVs, preliminary data suggest that at least some 
RAVs (M414T, S556G) may tend to persist during long-term follow-up for at least one year after 
treatment failure. Interestingly, the persistence rate of NS5B RAVs which occur together with 
NS5A RAVs appears to be higher in comparison to isolated NS5B RAVs [71]. 
 
Although RAVs are almost always observed in patients with virologic breakthrough during 
treatment, in relapse patients the detection rate of RAVs varies between 53-91% depending on the 
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duration of treatment, the DAA class and regimen [72-76]. This is most likely explained by the low 
sensitivity of the DNA sequencing method used, potential rapid reversion to wild-type between end-
of-treatment and the day of blood sampling for sequence analysis and a very low frequency of 
isolates containing RAVs within HCV quasispecies. Moreover, in patients with short duration of 
DAA-based antiviral therapies, wild-type virus may not be completely eradicated yet which also 
justifies relapse with a predominantly wild-type variant. 
 
All oral DAA combination therapies have exhibited high efficacy in the majority of patients with 
chronic hepatitis C. However, given the large number of infected individuals around the world, 
treatment failure is still expected as a consequence -in most cases- of the combined presence of 
RAVs and negative predictive host or viral factors, reduced susceptibility to additional antiviral 
agents or suboptimal treatment duration. Therefore, the problem of persistence, transmission and re-
selection of RAVs will be more relevant in the near future [77]. 
 
5. HCV drug resistance testing 
 
HCV resistance testing is fundamental to understand the clinical impact of drug resistance, optimize 
treatment schemes, increase SVR rates and reduce treatment failure. In clinical research or in the 
clinical setting, the available tools could be used either to determine the individual variant pattern of 
a patient’s quasispecies (genotypic analysis) or to characterize resistance substitutions (phenotypic 
analysis) in samples collected at baseline (pre-treatment), in case of virological breakthrough or 
relapse (virologic failure), and after treatment cessation (follow-up period).  
 
The genotypic analysis is based on sequencing technologies which include population sequencing 
(also called direct sequencing) [78,79], clonal sequencing [80,81] and next-generation sequencing 
(NGS) [82-84]. The direct sequencing of the HCV genome only exhibits appropriate sensitivity to 
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determine those dominant HCV variants that are present in the sample’s quasispecies with a 
frequency >20%; thus, it is a method useful for generating a consensus sequence. For many years, 
the only alternative method to population sequencing was genetic cloning followed by Sanger 
sequencing. Due to the fact that each clonal sequence represents a single variant present in the viral 
population, this technique shows high sensitivity to detect minor viral variants. However, the 
number of clones that can be analyzed is limited and the method is time-consuming and laborious. 
As a consequence, clonal sequencing is now being replaced by deep-sequencing technologies, as 
they allow reliable and fast detection of numerous viral variants with a frequency down to 0.5-1% 
[85]. 
 
The choice of one method over the other mainly depends on the aim of research and time point of 
sample collection. For example, pre-treatment samples are analyzed to detect the pre-existence of 
known or unknown resistance substitutions and/or provide a comparator for on- and post-treatment 
changes. Because of its high sensitivity, baseline resistant variants are more frequently revealed 
with NGS targeting short regions of a specific gene for quasispecies analysis [86,87]. On the other 
hand, at the time of virological breakthrough or relapse, it is important to identify aminoacid 
changes relative to baseline that confer resistance to the administered drugs. This type of analysis is 
best performed by NGS or clonal sequencing to describe quasispecies changes. Finally, in the 
follow-up period, population sequencing would useful if the resistant variant is present as a 
dominant viral population, but more sensitive techniques (i.e., clonal sequencing or NGS) are 
required to fully characterize the dynamics of RAV decay after treatment cessation. 
 
Due to the error-prone activity of the HCV polymerase, all possible variants are continuously 
generated in the mixture of viral populations [88]. Therefore, all above-mentioned sequencing 
methods may miss some RAVs as a result of their low frequencies within HCV quasispecies below 
the detection limits of available assays. In addition, other methodological restrictions such as non-
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amplification based on HCV RNA secondary structures and primer selection may increase the lack 
of detection of RAVs.  
In some cases, the inability to explain virologic failure requires the selection of candidate resistance 
substitutions detected in treated patients to perform phenotypic assays. In order to ensure an 
accurate assessment of the level of reduced susceptibility conferred by the selected substitution and 
a correct evaluation of its viral fitness cost, it is recommended to carry out this analysis by using 
site-directed mutagenesis or viral sequence insertion on a chimeric replicon backbone with the same 
genotype as the original isolate. In addition, to take into account the quasispecies distribution of 
HCV populations and the fact that resistant substitutions are present in mixtures of viral variant 
populations, phenotypic assays are best performed on a mixture of isolated clones [89].  
 
The usefulness of performing HCV resistance testing before starting a DAA treatment scheme is 
still under debate [90]. However, in some situations, resistance testing can be suitable in the clinical 
practice to decide which DAA is the best treatment option for a given patient.  
 
In the case of treatment-naive patients and patients after failure with pegIFN/RBV treatment, DAA 
resistance testing is not justified as it has been reported that treatment success with these new drugs 
occurs in high rates independently of the pre-existence of RAVs. For regimens that include DAAs 
with high antiviral activities and high genetic barrier to resistance, the presence of pre-treatment 
RAVs is related to a small reduction of SVR rates. In these cases, it is important to take into 
consideration additional predictors of response such as the stage of liver fibrosis or baseline viral 
load. 
However, a well-known exception is the Q80K substitution which confers resistance to NS3 
protease inhibitors. Unlike other RAVs to this group of DAAs, Q80K exhibits no loss of replicative 
fitness in the majority of patients and a high probability of pre-existence in HCV GT1a. 
International guidelines recommend testing for the presence of Q80K in DAA-naive patients 
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infected with HCV subtype 1a who are being considered for treatment with SMV plus pegIFN/RBV 
in cirrhotic patients due to the relative high frequency of pre-existing Q80K variants in GT1a in 
South American (9%), European (18%) and North American populations (48%) [91]. It has been 
reported that SVR rates in treatment-naive HCV GT1a infected patients with and without Q80K 
were 58% and 84%, respectively. Therefore, SMV-based triple therapy is not recommended in 
patients with detectable Q80K substitution at baseline.  
 
In regions with economic limitations, pre-treatment resistance testing may be cost effective in order 
to avoid virologic failure and the need of retreatment due to the high costs of these new drugs. In 
addition, HCV resistance testing may also be useful to select optimal treatment schemes in patients 
with shortened treatment duration, in those with liver cirrhosis, or in patients experiencing 
virological breakthrough or post-treatment relapse [92], particularly when their treatment comprises 
NS5A inhibitors. Indeed, in contrast to NS3 protease variants, NS5A RAVs can remain detectable 
several years after treatment withdrawal in 85% of patients [93], as viral fitness seem not to be 
impaired. The AASLD/IDSA guidelines recommend testing for RAVs that confer decreased 
susceptibility to NS3 protease and to NS5A inhibitors, for retreatment of cirrhotic patients or other 
patients who require retreatment urgently when these patients have history of failure to NS5A 
inhibitor-containing regimen [94]. 
Currently, there is no available recommendation for patients who failed to all oral DAA regimens. 
A proposed approach is longer retreatment with the same class of drugs although lower SVR rates 
are expected. Due to the high probability of the presence of multiple RAVs as well as the 
accumulation of negative predictive factors in these patients, monitoring resistance for the 
persistence of RAVs may be useful to determine the most appropriate and effective DAAs for 
second-line therapy, thus reinforcing the need of resistance testing in the context of virological 
failure in the clinical setting. Up to now, it is suitable to wait for results of clinical studies or in case 
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of urgent need of retreatment, select a different class of DAAs and take data obtained from 
resistance analysis into thorough consideration [95]. 
 
6. Expert Opinion  
 
The confluence of high viral replication turnover and the error-prone nature of the virus polymerase 
accounts for the large genetic variability displayed by HCV. Within each single infected person, the 
dynamic quasispecies nature of the viral population explains that mutations causing reduced 
susceptibility to antivirals are constantly been produced and that they would be selected under drug 
pressure. Combination antiviral therapy may overcome viral escape due to drug resistance in most 
instances and halting viral replication for time enough would lead to HCV elimination. This is in 
contrast with HIV or HBV, for which there is no stable cellular reservoir for the HCV genomic 
material, namely proviral DNA in HIV and cccDNA in HBV [96]. In the latest, antiviral treatment 
generally must be keep forever. 
 
Viral gene sequencing may recognize drug resistance substitutions for almost all DAA, with rates 
depending on HCV geno/subtype [12] and sensitivity of methods used. The choice of the methods 
for RAV testing depends on the research subject and on the sensitivity expected from the 
sequencing technique, and on the financial supports of each clinical laboratory. As the investigation 
of RAVs has to be performed on several genomic regions, with the use of different classes of DAAs 
in combination, could therefore gain from a complete genome sequencing techniques [97]. In our 
opinion, the use of NGS in the clinical laboratory and thus the implementation of HCV whole-
genome sequencing in clinical practice could help in identifying compensatory mutations located on 
the outside of the usually investigated regions, directly targeted by antiviral drugs, and recombinant 
or rare viral types. Besides expanding genomic region coverage, deep sequencing methods may 
provide unique information on the impact of minor quasispecies that otherwise would be missed 
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using crude population sequencing. The study of both the natural history of HCV infection and drug 
resistance could therefore benefit from the advantages of new molecular tools. However, the rapid 
and constant evolution of assays and their original high costs tend to slow down as NGS is steadily 
entering clinical practice. 
 
Drug resistance in HCV has reached enough maturity to be considered a key factor in hepatitis C 
therapeutics. A reduced susceptibility to antiviral agents may be present in both drug-naive and 
treatment-experienced patients. The rate of natural polymorphisms at positions associated with drug 
resistance varies across HCV geno/subtypes and each antiviral agent [98]. In contrast, selection of 
drug resistance following treatment failure occurs in most instances, although long-term persistence 
is mainly a concern for NS5A inhibitors. Considerable progress is being made and next-generation 
DAAs are coming with activity against drug-resistant viruses to either NS5A or protease inhibitors. 
Moreover, these new agents are pangenotypic and exhibit higher resistance barrier [98]. 
 
The robustness of sofosbuvir against DAA resistance largely accounts for its pivotal inclusion 
within most current DAA regimen combinations, being taken along with NS5A inhibitors, protease 
inhibitors and/or non-nucleoside polymerase inhibitors. All of the latest exhibit low resistance 
barrier. Besides the well-characterized S282T mutation, two additional changes (C316N and 
L159F) have recently been shown to confer reduced susceptibility to sofosbuvir. Whereas codon 
282 changes dramatically impair viral fitness, C316N and L159F do not. Accordingly, they are 
recognized as naturally occurring polymorphisms in never treated patients, especially in persons 
infected with HCV GT1b [99]. 
 
Newer DAA are being designed that display greater resistance barrier and could allow building 
soon sofosbuvir-free, alternative therapeutic options, following the path of 3D for HCV GT1b. As 
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example, phase 3 trials are ongoing with ABT-530 plus ABT-493, drugs that are pangenotypic 
NS5A and protease inhibitors, respectively [98]. 
 
Although DAA failures generally occur in less than 5-10% of treated chronic hepatitis C patients, 
selection of drug resistance is the rule in most cases. Of note, most treatment failures are relapses 
rather than viral breakthroughs on therapy. HCV re-treatment options are available, but first-line 
therapeutic strategies should be optimized to efficiently prevent DAA failure due to baseline HCV 
resistance [100]. For patients with cirrhosis or in whom previous treatment with any HCV NS5A 
inhibitors has failed and require retreatment urgently, testing for RAVs that confer decreased 
susceptibility to NS3 protease inhibitors (eg, Q80K) and to NS5A inhibitors should be performed 
using commercially available assays prior to selecting HCV treatment regimen. Given that baseline 
NS5A RAVs are one of the strongest pre-treatment predictors of treatment outcome with certain 
regimens, testing for these RAVs should be considered prior to use of ledipasvir/sofosbuvir. If 
ledipasvir associated RAVs are detected consideration should be given to adding RBV to the 
regimen and extending therapy to 24 weeks; otherwise treatment with simeprevir, sofosbuvir, and 
RBV for 24 weeks is recommended. For patients who have both NS3 and NS5A inhibitor RAVs 
detected, limited data suggest a retreatment approach based on sofosbuvir combined with either 
grazoprevir/ elbasvir may be efficacious. 
 
Besides compromising therapeutic options, drug-resistant viruses may also be transmitted. This 
caveat is of particular concern for NS5A inhibitor resistance associated mutations that once selected 
may persist for years. Transmission of DAA-resistant viruses may occur from patients that have 
failed drugs within this family and are engaged in high-risk practices, i.e., needle sharing among 
injection drug users or promiscuous sex among men who have sex with men. As proof of concept, 
sexual transmission of protease inhibitor resistant HCV has already being reported [77]. However, 
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the major concern is for NS5A inhibitors, given that resistance mutations to these compounds 
generally persist for years and produce wide cross-resistance to most agents within this family. 
 
Implementation of HCV drug resistance testing is challenged by the lack of commercial assays, 
difficult interpretation rules, and the rapid progress of the HCV armamentarium with next-
generation DAA that would overcome the impaired response to current DAA driven by resistance-
associated mutations, present either at baseline or following prior treatment failure. The usefulness 
of resistance testing in the clinical setting requires continued scrutiny as the use of different classes 
of DAAs for chronic HCV infection becomes increasingly widespread. Not all baseline and 
emergent RAVs will actually confer clinically significant drug resistance. HCV drug resistance 
testing prior to ﬁrst-line therapy currently is not recommended [95]. Indeed, the SVR rates are very 
high both in patients without and with detectable amounts of pre-existing RAVs; therefore, the 
detection of RAVs will not influence the treatment decision. Resistance testing may be useful in 
patients experiencing virological breakthrough or post-treatment relapse, particularly when their 
treatment comprises NS5A inhibitors. So in the context of DAA failure, monitoring resistance for 
the persistence of RAVs will lead to better management of second-line therapy. Otherwise, the 
usefulness of performing HCV resistance testing before starting a DAA treatment scheme is still 
under debate. However, the elevated costs of all-oral DAA therapies may push tailoring therapy, 
and in some situations like in patients with advanced cirrhosis, also baseline resistance testing can 
be suitable in the clinical practice to decide which DAA is the best (cost-effective) treatment option 
for a given patient.  
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Table 1. Direct acting antiviral (DAA) agents approved 
 
 
CLASS OF DAAs 
 
 
POTENCY 
 
GENOTYPIC 
COVERAGE 
 
BARRIER TO 
RESISTANCE 
 
CROSS 
RESISTANCE 
 
NS5B 
nucleos(ti)de 
analogue  
Inhibitors 
 
First  
generation 
 
SOFOSBUVIR 
 
High 
 
Pan-genotypic 
 
High 
 
High 
 
NS5B non 
nucleoside  
Inhibitors 
 
First  
generation 
 
DASABUVIR 
 
Low 
 
Limited to  
genotypes 1 (1b >1a) 
 
Low 
 
Low 
  
 
 
 
 
 
 
 
 
NS3-4A 
protease 
Inhibitors 
 
 
 
 
 
 
First  
generation 
 
1° 
wave 
 
TELAPREVIR 
 
Medium 
Limited to GT1  
(1b > 1a) 
 
Low 
 
High 
 
BOCEPREVIR 
 
Medium 
Limited to GT1  
(1b > 1a) 
 
Medium 
 
High 
 
 
 
2° 
wave 
 
 
SIMEPREVIR 
 
High 
Across all but 
genotype 3 
 
Low 
 
High 
 
PARITAPREVIR 
 
High 
Across all but 
genotype 3 
 
Low 
 
High 
 
ASUNAPREVIR 
 
High 
Limited to GT1  
(1b > 1a) 
 
Medium 
 
High 
 
VANIPREVIR 
 
High 
Across all genotypes 
less effective for GT3 
 
Intermediate 
 
High 
 
 
Second  
generation 
 
GRAZOPREVIR 
 
Very High 
 
GT1, GT4 and GT6 
 
High 
 
Low 
 
VOXILOPREVIR  
 
Very High 
 
Pan-genotypic 
 
High 
 
Low 
 
ABT-493 
 
Very High 
 
Pan-genotypic 
 
Intermediate 
 
High 
 
 
 
 
 
 
NS5A  
Inhibitors 
 
 
First  
generation 
 
DACLATASVIR 
 
Very High  
 
Pan-genotypic 
 
Low 
 
High 
 
LEDIPASVIR 
 
High  
 
GT1, GT4 and GT5 
 
Low 
 
High 
 
OMBITASVIR 
 
High  
 
GT1 and GT4  
 
Medium  
 
High 
 
 
 
Second 
generation 
 
ELBASVIR 
 
Very High  
 
GT1, GT4 and GT6 
 
High 
 
Low 
 
VELPATASVIR 
 
Very High 
Across all genotypes 
less effective for GT3 
 
High 
 
Low 
 
ABT-530 
 
Very High 
 
Pan-genotypic 
 
High 
 
Low 
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Table 2. The current recommended treatment options for each genotype for HCV-monoinfected or 
HCV/HIV coinfected patients with chronic hepatitis C without or with cirrhosis  (EASL. 
Recommendations on treatment of hepatitis C 2015).  
 
 GENOTYPE 
 
 
IFN-FREE REGIMENS 
HCV-monoinfected or 
HCV/HIV coinfected 
patients with chronic 
hepatitis C without 
cirrhosis 
HCV-monoinfected or 
HCV/HIV coinfected 
patients with chronic 
hepatitis C with 
compensated cirrhosis 
Sofosbuvir + Ribavin (RBV) 
 
2, 3 2 
Sofosbuvir/Ledipasvir ± RBV 
 
1,4,5,6 without RBV  1,4,5,6 with RBV  
or without RBV 
Ombitasvir/Paritaprevir/Ritonavir  
+ Dasabuvir ± RBV 
1 with RBV (Gt1a) or 
without RBV (Gt1b) 
1 with RBV 
Sofosbuvir + Simeprevir ± RBV 
 
1,4 without RBV 1, 4 with RBV or 
without RBV 
Sofosbuvir + Dacalatsvir ± RBV 
 
All without RBV All with RBV  
or without RBV 
Ombitasvir/Paritaprevir/Ritonavir ± RBV 
 
4 with RBV 4 with RBV 
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Table 3. Main resistance mutations associated with HCV NS3/4A protease inhibitors in genotypes 
(GT) 1a and 1b. 
 
NS3/4A 
Inhibitors 
HCV NS3 Protease 
Wild-type aminoacid, position and resistance-associated substitution(s) 
 
 Genotype 
(GT) 
V36 T54 V55 Y56 Q80 S122 R155 A156 D168 I/V170 
Simeprevir GT1a     Q80K
/R 
S122
G/R 
R155
K 
 D168
/E/V 
/A/H 
I/V170
T 
GT1b     Q80
R/K/
H 
S112
A/I/T 
R155
Q 
 D168
/E/V 
/A/F/
H/T 
 
Asunaprevir GT1a V36L
/M 
  Y56H
/L 
  R155
K 
 D168
E 
/A/T/
V/Y 
 
GT1b V36G  V55A Y56H
/L 
Q80R
/K 
S122
D/G/I
/N/T 
R155
G 
/Q 
 D168
E/V/
Y 
/F/G/
H/T 
I/V170
A 
Paritaprevir GT1a V36A
/M 
 V55I Y56H   R155
K 
 D168
A/V/
Y 
/E/F/I
/L/N/
T 
 
GT1b    Y56
H 
    D168
V 
/A/K/
F/H/I/
L 
 
Vaniprevir GT1a       R155
K 
 D168
T/V/
Y 
/A/F/
H/N/
S 
 
GT1b         D168
H/T/
V 
/A/E/
F 
 
Grazoprevier GT1a V36L
/M 
  Y56H Q80K S122
G 
R155
K/T 
A156
A/T 
D168
N/A/
V 
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GT1b  T54S      A156
T 
 V170I 
*The amino acid substitutions most commonly observed in patients who did not achieve SVR are visualized in bold.  
 
 
Table 4. Main resistance mutations associated with HCV NS5B Polymerase inhibitors in genotypes 
(GT) 1a and 1b. 
 
NS5B 
Inhibitors 
HCV NS5B Polymerase inhibitors 
Wild-type aminoacid, position and resistance-associated substitution(s) 
 
 Genotype 
(GT) 
L159 S282 V321A C316 M414 S556 
Sofosbuvir GT1a L159F S282T/R V321A C316N   
GT1b L159F S282T  C316N   
Dasabuvir GT1a    C316Y M414T/I S566G/R 
GT1b    C316Y M414T/I S566G/R 
*The amino acid substitutions most commonly observed in patients who did not achieve SVR are visualized in bold.  
 
  
 
Table 5. Main resistance mutations associated with HCV NS5A inhibitors in genotypes (GT) 1a 
and 1b. 
 
NS5A 
Inhibitors 
HCV NS5A 
Wild-type aminoacid, position and resistance-associated substitution(s) 
 Genotype 
(GT) 
M/L28 Q/R30 L31 H/P58 Y93 
Daclatasvir GT1a M28T/A/S/V Q30E/H/R/D/G/K/T L31M/I/V H58D/R Y93H/N/C 
GT1b L28M/T R30G/H/P/Q L31M/V/F/I P58S Y93H/N 
Ledipasvir GT1a M28T/A Q30E/H/R/K/L/R/Y L31M/P H58D Y93C/H/N/S 
GT1b   L31I/M/V  Y93H/C 
Ombitasvir GT1a M28T/V/A Q30R/K/E  H58D Y93C/H/N/S 
GT1b     Y93H/C 
Elbasvir GT1a M28T/G/A Q30R/H/Y/L L31M/V H58D Y93H/N 
GT1b   L31M/F  Y93H 
*The amino acid substitutions most commonly observed in patients who did not achieve SVR are visualized in bold. 
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Figure 1. Emergence and selection of drug resistant variants. 
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